Intravitreal administration

Oculis Announces Upcoming Presentation of Phase 2 Data of OCS-01 in Patients with Diabetic Macular Edema (DME) at Angiogenesis, Exudation, and Degeneration 2020

Retrieved on: 
Wednesday, January 22, 2020
Medicine, Clinical medicine, Health, Macular edema, Diabetic retinopathy, Novartis, Intravitreal administration, Monoclonal antibodies

"At present, only intravitreal agents are available to treat chronic retinal diseases such as diabetic macular edema," saidRiad Sherif, M.D., Chief Executive Officer of Oculis.

Key Points: 
  • "At present, only intravitreal agents are available to treat chronic retinal diseases such as diabetic macular edema," saidRiad Sherif, M.D., Chief Executive Officer of Oculis.
  • "A topical treatment option may help serve an unmet need for a non-injectable, effective, safe, adaptable, and readily accessible treatment.
  • The Phase 2 trial data to be presented at this conference is the first controlled study of OCS-01 for the treatment of DME."
  • OCS-02 is a novel topical anti-TNF alpha antibody in Phase 2 for inflammatory eye diseases and was in-licensed from Novartis.

Adverum Biotechnologies to Present at Upcoming Conferences

Retrieved on: 
Wednesday, December 18, 2019
Medicine, Clinical medicine, Adverum Biotechnologies, Intravitreal administration, Health, Macular degeneration

MENLO PARK, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at upcoming conferences:

Key Points: 
  • MENLO PARK, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the company will present at upcoming conferences:
    Webcast: A live audio webcast will be accessible under Events and Presentations in the Investors section of the company's website.
  • The archived audio webcast will be available on the Adverum website following the presentation for 30 days.
  • Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
  • For more information, please visit www.adverum.com.

Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

Retrieved on: 
Tuesday, November 26, 2019
Diketones, Glucocorticoids, Chemistry, Functional groups, Medicine, Alimera Sciences, Intravitreal administration, Piper Jaffray, Fluocinolone acetonide, Retina, Ophthalmology, Fluocinolone

ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera or Company), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3, 2019.

Key Points: 
  • ATLANTA, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera or Company), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, President and Chief Executive Officer of Alimera, will participate in the 31st Annual Piper Jaffray Healthcare Conference in New York City on December 3, 2019.
  • Interested investors may contact the conference organizers via the Piper Jaffray website, www.piperjaffray.com .
  • Alimera, founded in June 2003, is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the management of retinal diseases.
  • The Companys primary product is ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into the back of the eye.

Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule

Retrieved on: 
Thursday, October 24, 2019
Science, Biotechnology, Research, Pharmaceutical, Optical, Health, FDA, Clinical trials, Medicine, Clinical medicine, Drugs, Glucocorticoids, Pregnanes, RTT, Dexamethasone, Organofluorides, Otologicals, Intravitreal administration, AR-1105, Aerie Pharmaceuticals, Inc.

The Phase 2 study (AR-1105-CS201), conducted at 19 centers in the United States, had an enrollment target of 45 patients.

Key Points: 
  • The Phase 2 study (AR-1105-CS201), conducted at 19 centers in the United States, had an enrollment target of 45 patients.
  • The trial is evaluating two formulations of AR-1105 (CF-1 and CF-2) that differ in the duration of dexamethasone release.
  • The primary objectives of the trial are to evaluate the safety, tolerability and efficacy of the AR-1105 dexamethasone intravitreal implant.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration

Retrieved on: 
Saturday, October 12, 2019
Medicine, Clinical medicine, Ophthalmology, Breakthrough therapy, Genentech, Ranibizumab, Macular degeneration, Retina, Intravitreal administration, Vascular endothelial growth factor, Anti–vascular endothelial growth factor therapy, Macular edema

In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.

Key Points: 
  • In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains comparable to monthly ranibizumab.
  • Through week 104, patients received Abicipar 2 mg every 8-weeks or every 12-weeks or ranibizumab 0.5 mg every 4 weeks.
  • At week 104 in the pooled Phase 3 data, the proportion of patients with stable vision was 93%, 90% and 94% in 8-week Abicipar; 12-week Abicipar and 4-week ranibizumab treatment regimens, respectively.
  • "Current anti-VEGF treatments for neovascular age-related macular degeneration require frequent intravitreal injections," said Rahul N. Khurana, M.D., Northern California Retina Vitreous Associates Medical Group.

 Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

Retrieved on: 
Wednesday, October 9, 2019
Health, Other Health, Pharmaceutical, Optical, Biotechnology, Clinical medicine, Medicine, Intravitreal administration, Glaucoma, Health, Monoclonal antibodies, Multiple sclerosis

Annexon Biosciences , a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain, today announced encouraging results from a Phase 1b dose-ranging clinical trial to evaluate its anti-C1q antibody, ANX007, in patients with glaucoma.

Key Points: 
  • Annexon Biosciences , a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain, today announced encouraging results from a Phase 1b dose-ranging clinical trial to evaluate its anti-C1q antibody, ANX007, in patients with glaucoma.
  • In the Phase 1b trial, ANX007 was well-tolerated and resulted in full target engagement and inhibition of C1q in the eye for at least four weeks following a single intravitreal treatment.
  • In a Phase 1b clinical trial of ANX007, glaucoma patients (n=17) were treated with multiple doses of intravitreal ANX007.
  • Annexon has completed a Phase 1b clinical trial of ANX007 in glaucoma and plans to advance ANX007 into later-stage clinical trials for geographic atrophy and other ophthalmic diseases.

GenSight Biologics Reports Evidence of GS010 DNA Transfer to Contralateral Eye of Primates Unilaterally Injected With GS010 Gene Therapy

Retrieved on: 
Wednesday, October 9, 2019
Health, Clinical trials, Pharmaceutical, Optical, Biotechnology, Dosage forms, Intravitreal administration, Molecular biology, Life sciences, Biology, Biotechnology, Emerging technologies, Medical genetics, GenSight Biologics, GS010, Leber Hereditary Optic Neuropathy (LHON), REVERSE and RESCUE, REFLECT

The contralateral effect did not conform to expectations for gene therapies administered to only one eye.

Key Points: 
  • The contralateral effect did not conform to expectations for gene therapies administered to only one eye.
  • Three test monkeys were given an intravitreal injection of GS010 in their right eyes and not injected in their left eyes.
  • The dosage of GS010 was calibrated to be the allometric equivalent of that used in the GS010 Phase III trials.
  • The highly sensitive and accurate test contains a protocol that specifically targets a portion of the GS010 DNA and can detect the GS010 DNA matrix.

ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO

Retrieved on: 
Monday, October 7, 2019
Dosage forms, Intravitreal administration, Dose, Injection

The results will be announced in a press release on October 10, 2019 and management will host an investor conference call at 8:00 a.m.

Key Points: 
  • The results will be announced in a press release on October 10, 2019 and management will host an investor conference call at 8:00 a.m.
  • Patients are receiving four intravitreal injections of sepofarsen into one eye; one injection every three months, with the other eye remaining untreated.
  • Two dose levels are being tested, 80 g (160 g loading dose) and 160 g (320 g loading dose).
  • Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.

Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Tuesday, October 1, 2019
Organic compounds, Diketones, Glucocorticoids, Chemistry, Chemical compounds, Diols, Intravitreal administration, Ophthalmology, Fluocinolone acetonide, Fluocinolone

Five ePosters featuring long-term clinical efficacy and safety data for ILUVIEN will be available for viewing at the conference, with three having subsequent discussion sessions following their initial availability.

Key Points: 
  • Five ePosters featuring long-term clinical efficacy and safety data for ILUVIEN will be available for viewing at the conference, with three having subsequent discussion sessions following their initial availability.
  • We continue to invest in generating additional clinical data and real-world experience studies from the more than 20,000 ILUVIEN injections to date, and plan to share additional data at future ophthalmology conferences.
  • The American Academy of Ophthalmology (AAO) is the worlds largest association of eye physicians and surgeons.
  • ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is a sustained release intravitreal implant, injected into the back of the eye.

EyePoint Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

Retrieved on: 
Thursday, September 26, 2019
Organic compounds, Medicine, Chemistry, Glucocorticoids, Acetonides, Diketones, Pregnanes, Diols, Fluocinolone acetonide, Intravitreal administration, Fluocinolone, Lomb

WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:05 AM ET.

Key Points: 
  • WATERTOWN, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that Nancy Lurker, President and Chief Executive Officer, is scheduled to present at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 10:05 AM ET.
  • A live audio webcast and subsequent archived replay of the presentation may be accessed via the Investors section of the Company's website at www.eyepoint.com.
  • Retisert (fluocinolone acetonide intravitreal implant), for non-infectious posterior segment uveitis, is licensed to and sold by Bausch & Lomb, Inc.
  • To learn more about the Company, please visit www.eyepointpharma.com and connect on Twitter and LinkedIn.